Trial Profile
Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary) ; Albumins; Phytomenadione; Silymarin; Spironolactone/furosemide
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Jun 2018 New trial record